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SARS-CoV-2 vaccines 
and donor recruitment 
for FMT
Due to its clear benefits in the 
management of recurrent Clostridioides 
difficile infection, faecal microbiota 
transplantation (FMT) has been 
advocated by the gastroenterological 
community as a non-postponable 
procedure to be continuously delivered 
during the COVID-19 pandemic.1
Therefore, specific recom men-
dations have been released to 
reorganise the workflow of FMT 
during the pandemic to avoid the 
potential risk of transmission of 
severe acute respiratory syndrome 
coronavirus 2 (SARS-CoV-2) through 
the FMT procedure or the donor–
recipient faecal transfer.2 Briefly, these 
recommendations included the use 
of remote assessment of patients 
and donors whenever possible, the 
expansion of donor screening with 
questionnaires and laboratory testing 
aimed at excluding SARS-CoV-2 
infection, and the application of 
specific safety measures during the 
endoscopic FMT procedure.1,3
The SARS-CoV-2 vaccination 
campaign has started worldwide in the 
past few weeks. One major category of 
vaccines (developed both by BioNTech 
and Pfizer, and also by Moderna and 
the National Institute of Allergy and 
Infectious Diseases) is based on mRNA 
products that encode a genetically 
modified SARS-CoV-2 spike protein. 
These vaccines are promising, with 
93–95% efficacy and minimal side-
effects. An additional emerging class 
of vaccines, that uses a non-replicating 
adenovirus vector with SARS-CoV-2 
spike protein, including the ChAdOx1 
nCoV-19 University of Oxford and 
AstraZeneca vaccine, has also been 
given at least temporary authorisation 
in some countries (eg, Argentina, 
Brazil, and the UK, among others). 
Finally, various vaccine technologies, 
including live attenuated vaccines, are 
being investigated.
Overall, these efforts are expected to 
give a considerable boost to the fight 
against COVID-19. Consequently, an 
important discussion in the field of 
human tissue transfer is required, and 
specifically in FMT. We must consider 
what effect vaccination will have 
on FMT in clinical practice based on 
current knowledge and data.
The first question is whether there 
should be a waiting period between 
SARS-CoV-2 vaccination and donor 
screening. In our latest consensus 
report on stool biobanking, a recent 
history (<2 months) of vaccination 
with a live attenuated virus was 
among the exclusion criteria for stool 
donors in case of a possible risk of 
transmission.4 For vaccines based on 
mRNA technologies (rather than live 
attenuated virus), it does not seem 
feasible that there would be a risk 
for transmission, and this exclusion 
criterion can be disregarded, as 
already suggested for blood donors.5 
Nonetheless, available vaccines have 
been associated with some adverse 
events, including fatigue, nausea, 
fever, headache, myalgia, arthralgia, 
and pain at the injection site, among 
others, which can last several days after 
the vaccination. As these symptoms 
can overlap with those assessed 
during donor screening (at the entry 
questionnaire and the day of each 
donation), it might be pragmatic to 
wait 7–10 days from vaccination before 
evaluating potential donors to avoid 
the risk of inappropriate rejection of 
candidates. It could also be reasonable 
to follow such an approach for vaccines 
based on viral vectors, as suggested in 
UK blood donation guidelines.6 Live 
attenuated virus vaccines are being 
developed and could become available 
for clinical use, but we still do not have 
data for risk of viral transmission with 
these candidate vaccines. Therefore, 
the safest approach might be to adhere 
to current guidelines for this type of 
vaccine and wait at least 2 months 
after vaccination before donor 
screening.4 At the initial evaluation, all 
potential donor candidates should be 
asked about SARS-CoV-2 vaccination 
and, if vaccinated, a window of time 
(the length depending on the type of 
vaccine) should elapse before moving 
forward with full screening (appendix).
Another question is whether donors 
who have been vaccinated require 
clinical and laboratory investigations 
for COVID-19 during screening. 
Although it is recognised that current 
vaccines are effective in preventing 
COVID-19, uncertainty remains 
regarding their effect on transmission 
of the virus. More specifically, there 
are no available data for the presence 
of SARS-CoV-2 in the faeces of 
individuals who have been vaccinated 
if exposed, and of the risk of faecal–
oral transmission of the virus. Finally, 
as we do not yet know how long 
vaccine immunity lasts, it would be 
difficult to predict the duration of 
the donor’s protection against the 
virus. These open questions prevent 
any recommendation to change or 
streamline the current indications 
for the screening of stool donors, as 
current data do not yet assure us with 
a satisfactory level of safety for FMT.
Irrespective of the above consid-
erations, because different steps of 
the FMT process (eg, the evaluation of 
donors and patients, the manipulation 
of faeces, the FMT procedure itself, 
and the follow-up of patients) 
could expose donors, patients, and 
physicians to SARS-CoV-2 infection, 
it is reasonable and wise to strongly 
encourage vaccination.
In conclusion, although the roll-
out of vaccines is expected to be a 
turning point in the pandemic, the 
alert level applied to the FMT work-
flow to prevent the transmission of 
SARS-CoV-2 cannot be reduced until 
further data emerges.
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